Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Q2 2026 net loss widens to $42.3 million; cash falls to $174.6 million

Negative Impact 3 of 5 earnings Written later

Zentalis reported a second-quarter 2026 net loss of $42.3 million, or $0.59 per share, up from $26.9 million, or $0.37 per share, a year earlier, as operating expenses rose to $44.4 million. Cash, cash equivalents and marketable securities declined to $174.6 million from $245.9 million at December 31, 2025, and the company says that balance funds operations into late 2027, which matters to shareholders because the company has no approved product and depends on the azenosertib program.

Key points

  • Net loss of $42.3 million ($0.59 per share) for the quarter ended June 30, 2026, versus $26.9 million ($0.37 per share) for the same quarter of 2025
  • R&D expenses of $35.2 million, up from $27.6 million, including a $7.0 million milestone payment to Recurium IP Holdings, LLC tied to the start of the Phase 3 ASPENOVA trial
  • Cash and marketable securities of $174.6 million at June 30, 2026, down from $245.9 million at December 31, 2025; runway stated into late 2027
  • DENALI Part 2 topline readout expected in 1H 2027

The filing

CompanyZentalis Pharmaceuticals, Inc. (ZNTL)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:10 PM ET
Accession number0001725160-26-000061

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.